Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

Oct 25 2019

• By Joseph Haas

Close Up Of Senior Man At Home Suffering With Arthritis - Image — Rheumatoid arthritis may be the first of several indications for filgotinib

Related Content

Gilead’s Descovy Nabs Limited HIV Prophylaxis Indication Pending A New Study In Women

Oct 04 2019

Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib

Dec 18 2015

Filgotinib Shaping Up To Be Success Story For Gilead and Galapagos

May 31 2018

$5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day

Jul 15 2019

Gilead To File Filgotinib For RA in 2019, Earlier Than Forecast

Jul 02 2019

AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval

Aug 16 2019

Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate

Oct 24 2019

Related Companies

Gilead Sciences, Inc.

Galapagos NV

AbbVie Inc.

Vertex Pharmaceuticals Incorporated

Alexion Pharmaceuticals Inc.

BioMarin Pharmaceutical Inc.

Incyte Corporation

Additional Topics

Business Strategies Drug Approval Standards Commercial Immune Disorders BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window